CDKN1B and intrahepatic cholangiocarcinoma: Meanwhile, YTHDF2 silencing restrains ICC resistance to the exposure of cisplatin by reversing the degradation of cyclin-dependent kinase inhibitor 1B (CDKN1B) mRNA (190).